ArticleFrontiers in microbiology2026
Eravacycline monotherapy and combination therapy against KPC-2- and NDM-1-co- producing
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond β-Lactams: Defining the Role of Eravacycline in Multidrug-Resistant and Metallo-β-Lactamase-Producing Infections.Antibiotics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The emergence of carbapenem-resistant Methods: We analyzed the molecular epidemiology of 42 K2N1-CRKP strains and evaluated their susceptibility to eravacycline. The Results: All 42 strains belonged to ST11. Among them, 92.8% (39/42) were susceptible to eravacycline (MIC50/90: 1 μg/mL; range: 0.5-2 μg/mL). Two strains (KP17, KP18) were resistant to both eravacycline and polymyxin B. The eravacycline-polymyxin B combination showed synergistic activity against 9.5% (4/42) of isolates, including the two dual-resistant strains. No interaction was observed for eravacycline combined with ceftazidime-avibactam, meropenem, or amikacin. Time-kill assays confirmed the rapid, sustained bactericidal activity of the eravacycline-polymyxin B combination against K2N1-CRKP. In the Conclusion: Eravacycline demonstrates potent
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.